TY - JOUR
T1 - Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia
T2 - Implications for early intervention strategies
AU - Neelakantan, Pratap
AU - Gerrard, Gareth
AU - Lucas, Claire
AU - Milojkovic, Dragana
AU - May, Philippa
AU - Wang, Lihui
AU - Paliompeis, Christos
AU - Bua, Marco
AU - Reid, Alistair
AU - Rezvani, Katayoun
AU - O'Brien, Stephen
AU - Clark, Richard
AU - Goldman, John
AU - Marin, David
N1 - Publisher Copyright:
© 2013 by The American Society of Hematology.
PY - 2013
Y1 - 2013
N2 - Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6 months after starting treatment with tyrosine kinase inhibitors strongly predicts clinical outcomes for patients with chronic myeloid leukemia. In this work, we asked whether the prognostic value of the 3-month transcript level could be improved by combining the 3- and 6-month results. We classified patients treated with imatinib and patients treated with dasatinib according to their transcript levels at 3 months and 6 months. The patients who met the 3-month landmark but failed the 6-month one had outcomes identical to those of patients who met both landmarks, whereas the patients who failed the first landmark but met the second one had prognoses similar to those who failed both landmarks. In summary, early intervention strategies can be based robustly just on the transcript level at 3 months. This trial was registered at www.clinicaltrials.gov as # NCT01460693.
AB - Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6 months after starting treatment with tyrosine kinase inhibitors strongly predicts clinical outcomes for patients with chronic myeloid leukemia. In this work, we asked whether the prognostic value of the 3-month transcript level could be improved by combining the 3- and 6-month results. We classified patients treated with imatinib and patients treated with dasatinib according to their transcript levels at 3 months and 6 months. The patients who met the 3-month landmark but failed the 6-month one had outcomes identical to those of patients who met both landmarks, whereas the patients who failed the first landmark but met the second one had prognoses similar to those who failed both landmarks. In summary, early intervention strategies can be based robustly just on the transcript level at 3 months. This trial was registered at www.clinicaltrials.gov as # NCT01460693.
UR - http://www.scopus.com/inward/record.url?scp=84878263769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878263769&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-11-466037
DO - 10.1182/blood-2012-11-466037
M3 - Article
C2 - 23380743
AN - SCOPUS:84878263769
SN - 0006-4971
VL - 121
SP - 2739
EP - 2742
JO - Blood
JF - Blood
IS - 14
ER -